Brief: Oryzon Submits Phase III Trial Protocol For BPD Drug Vafidemstat To FDA

ORYZON Genomics SA

23/06/2025 07:15

June 23 (Reuters) - Oryzon Genomics SA ORY.MC:

SUBMITS TO FDA CLINICAL TRIAL PROTOCOL FOR ITS PHASE III PORTICO-2 TRIAL OF VAFIDEMSTAT IN BORDERLINE PERSONALITY DISORDER (BPD) PATIENTS

PORTICO-2 TO EMPLOY TWO CLINICAL OUTCOME MEASURES FOR AGGRESSION AS PRIMARY ENDPOINT

TO EMPLOY OVERT AGGRESSION SCALE-MODIFIED (OAS-M) AS KEY SECONDARY ENDPOINT

ADDITIONAL SECONDARY ENDPOINTS TO EVALUATE BROADER CLINICAL IMPROVEMENTS IN BPD SYMPTOMATOLOGY AND LIFE QUALITY

Source text: ID:nCNMhTlnPF

Further company coverage: ORY.MC

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))